Versão HTML básica
376
Souza CA, Pagnano KB, Bendit I, Conchon M, Freitas CM, Coelho AM, Funke VA, Bernardo WM
Rev Bras Hematol Hemoter. 2012;34(5):367-82
G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the
poor prognostic significance of deletions of derivative chromosome 9 in
patients with chronic myelogenous leukemia. Blood. 2005;105(6):2281-6.
12. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV,
Verstovsek S, et al. Prognostic impact of deletions of derivative
chromosome 9 in patients with chronic myelogenous leukemia treated
with nilotinib or dasatinib. Cancer. 2011;117(22):5085-93.
13. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd
P, et al. Deletions of the derivative chromosome 9 occur at the
time of the Philadelphia translocation and provide a powerful and
independent prognostic indicator in chronic myeloid leukemia. Blood.
2001;98(6):1732-8. Comment in
:
Blood. 2001;98(9):2879-80.
14. Fourouclas N, Campbell PJ, Bench AJ, Swanton S, Baxter EJ, Huntly
BJ, et al. Size matters: the prognostic implications of large and small
deletions of the derivative 9 chromosome in chronic myeloid leukemia.
Haematologica. 2006;91(7):952-5.
15. Lee YK, Kim YR, Min HC, Oh BR, Kim TY, Kim YS, et al. Deletion
of any part of the BCR or ABL gene on the derivative chromosome 9
is a poor prognostic marker in chronic myelogenous leukemia. Cancer
Genet Cytogenet. 2006;166(1):65-73.
16. Vaz de Campos MG, Montesano FT, Rodrigues MM, Chauffaille Mde L.
Clinical implications of der(9q) deletions detected through dual-fusion
fluorescence in situ hybridization in patients with chronic myeloid
leukemia. Cancer Genet Cytogenet. 2007;178(1):49-56.
17. Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M,
Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori
L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli
AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M,
Rosti G, Testoni N; Gruppo Italiano Malattie EMatologiche dell’Adulto
(GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant
Philadelphia translocations: molecular-cytogenetic characterization and
prognostic influence on frontline imatinib therapy, a GIMEMAWorking
Party on CML analysis. Blood. 2011;117(25):6793-800.
18. Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S,
Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F,
Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G,
Baccarani M, Rosti G. Deletions of the derivative chromosome 9 do not
influence the response and the outcome of chronic myeloid leukemia
in early chronic phase treated with imatinib mesylate: GIMEMA CML
Working Party analysis. J Clin Oncol. 2010;28(16):2748-54.
19. Landstrom AP, Knudson RA, Dewald GW, Ketterling RP, Tefferi A.
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid
leukemia: clinical correlates and effect on imatinib mesylate treatment
outcome. Leuk Lymphoma. 2007;48(11):2137-40.
20. Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant
translocations in chronic myeloid leukemia. Cancer Genet Cytogenet.
2007;173(2):97-106.
21. Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S,
et al. Additional chromosome abnormalities, BCR-ABL tyrosine
kinase domain mutations and clinical outcome in Hungarian tyrosine
kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta
Haematol. 2012;127(1):34-42.
22. Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, et
al. Impact of additional chromosomal aberrations and BCR-ABL
kinase domain mutations on the response to nilotinib in Philadelphia
chromosome-positive chronic myeloid leukemia. Hematologica.
2010;95(4):582-8.
23. Haus O, Noworolska A, Laskowski M, Kuliszkiewicz-Janus M,
Kozlowska J, Harlozinska-Szmyrka A, et al. Prognostic significance of
secondary cytogenetic changes and nonspecific cross-reacting antigen
(NCA) in patients with Ph-positive chronic myeloid leukemia. Exp Mol
Pathol. 1990;52(2):235-42.
24. Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS, et al.
Additional chromosome abnormalities in chronic myeloid leukemia.
Kaohsiung J Med Sci. 2011(2);27:49-54.
25. Vranová V, Katina S, Kirschnerová G, Mistrík M, Lakota J, Horáková
J, et al. A significance of additional chromosomal aberrations and
other variables on post transplantation outcome of patients with CML.
Neoplasma. 2005;52(5):381-7.
26. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach
C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz
S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD,
Falge C, Kanz L, NeubauerA, Kneba M, Stegelmann F, Pfreundschuh M,
Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M,
Hasford J, Saussele S, Hehlmann R; SchweizerischeArbeitsgemeinschaft
für Klinische Krebsforschung (SAKK) and the German CML Study
Group. Impact of additional cytogenetic aberrations at diagnosis on
prognosis of CML: long-term observation of 1151 patients from the
randomized CML Study IV. Blood. 2011;118(26):6760-8.
27. Ahmed R, Naqi N, Hussain I, Khattak BK, Nadeem M, Iqbal J.
Presentating phases of chronic myeloid leukaemia. J Coll Physicians
Surg Pak. 2009;19(8):469-72.
28. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia.
Semin Hematol. 2003;40(1):79-86.
29. Cortes JE, Talpaz M, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli
A, et al. Staging of chronic myeloid leukemia in the imatinib era:
an evaluation of the World Health Organization proposal. Cancer.
2006;106(6):1306-15.
30. Cortes J. Natural history and staging of chronic myelogenous leukemia.
Hematol Oncol Clin North Am. 2004;18(3):569-84, viii.
31. Aguayo A, Couban S. State-of-the-art in the management of chronic
myelogenous leukemia in the era of the tyrosine kinase inhibitors:
evolutionary trends in diagnosis, monitoring and treatment. Leuk
Lymphoma. 2009;50(Suppl 2):1-8.
32. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes
F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen
JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl
A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE,
Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with
interferon and low-dose cytarabine for newly diagnosed chronic-phase
chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
33. Bonifazi F, De Vivo A, Rosti G, Tiribelli M, Russo D, Trabacchi E, et
al. Testing Sokal’s and the new prognostic score for chronic myeloid
leukaemia treatedwith alpha-interferon. Italian Cooperative Study Group
on Chronic Myeloid Leukaemia. Br J Haematol. 2000;111(2):587-95.
34. Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, et
al. Changes in the dynamics of the excess mortality rate in chronic
phase-chronic myeloid leukemia over 1990-2007: a population study.
Blood. 2011;118(16):4331-7.
35. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H,
Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM,
Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P,
Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G,
Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B,
Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.
Five-year follow-up of patients receiving imatinib for chronic myeloid
leukemia. N Engl J Med. 2006;355(23):2408-17.
36. Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM,
Kersten MJ, et al. Efficacy of escalated imatinib combined with
cytarabine in newly diagnosed patients with chronic myeloid leukemia.
Haematologica. 2010;95(6):914-21.
37. Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, et
al. Cytogenetic andmolecular responses to standard-dose imatinib in chronic